UAE-Based Healthtech BioSapien Secures $8 Million Pre-Series A

BioSapien, a UAE-based healthtech startup, has extended its Pre-Series A round to over $8 million. The startup, which specialises in cancer-focused drug delivery systems, raised the additional capital from UAE VC firm Globivest alongside a group of international and regional investors.

The funding will be used to advance BioSapien’s flagship product - a biodegradable implant designed to deliver chemotherapy directly to tumour sites. The solution aims to reduce systemic toxicity and improve targeted treatment outcomes for cancer patients. The latest capital injection will support regulatory approvals, including FDA pathways, preclinical studies, and commercial pilots in select international markets.

Founded in the US and now operating out of the UAE, BioSapien represents a growing trend of biotech startups relocating to or expanding within the region as healthcare innovation becomes a focal point for MENA investors. With the extended funding round, the company is also looking to expand its research team and build additional partnerships with healthcare providers.

The firm’s core mission is to transform how chemotherapy is delivered, making it more efficient, less invasive, and ultimately more effective. According to BioSapien, its technology has already shown promising results in initial lab and animal studies, and the startup is now preparing to move toward first-in-human trials.